Skip to main content
SpringerLink
Log in

Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cisplatin (CDDP) is a potent anticancer drug, and neurotoxicity is one of its most important dose-limiting toxicities. In this study we investigated the role of recombinant human erythropoietin (rhuEPO) for protection against CDDP-induced neurotoxicity. All experiments were conducted on female Wistar-albino rats. Animals were randomly assigned to three groups. Group A received only CDDP, group B received CDDP plus rhuEPO, and group C received only rhuEPO. Electroneurography (ENG) was done in the beginning and at the end of 7 wk, then the rats were sacrificed and the sciatic nerve was removed for histopathological examination.

The mean initial latency was 2.7438 ms in group A, 2.4875 ms in group B, and 2.62 ms in group C. After 7 wk of treatment, the latency was 2.4938, 2.6313, and 2.3900 ms, respectively. The difference in latencies was not statistically significant. The amplitude of compound muscle action potential (CMAP) was 12.8125 mV, 14.3875 mV, and 14.5600 mV before the treatment and 8.4875, 12.8250, and, 13.0800 mV after treatment, respectively. Amplitude of CMAP was significantly greater in rhuEPO-treated groups (groups B and C) compared to cisplatin only Group A. The mean area of CMAP was 12.2625, 12.3500, and, 12.2800 mV s before the treatment and 5.7125, 10.6463, and 9.1600 mV s after the treatment, respectively. The area of CMAP was significantly larger in rhuEPO-treated groups. In histopathological studies thick, thin, and total number of nerve fibers were 4053, 5050, and 9103, in group A, 5100, 8231, and 13331, in group B, and 5264, 6010, and 11274, in group C respectively. In the microscopic examination active myelinization process was observed in rhuEPO-treated groups. We concluded that at the given dose and schedule CDDP-induced motor neuropathy and rhuEPO prevented this neuropathy by sparing the number of normal nerve fibers and by protecting the amplitude and area of CMAP. We concluded that rhuEPO may also play a role in active myelinization and it is an active agent in protection against CDDP-induced peripheral neuropathy, warranting further clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. The Annals of Pharmacotherapy 1993; 27:1053–1073.

    Google Scholar 

  2. Aggarwal SK. A histochemical approach to the mechanism of action of cisplatin and its analogs. J Histochem Cytochem 1993; 41:1053–1073.

    PubMed  CAS  Google Scholar 

  3. Hammers FP, et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53:544–549.

    Google Scholar 

  4. Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M, Venturino P. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology 1994; 15:701–704.

    PubMed  CAS  Google Scholar 

  5. Cavaletti G, Minoia C, Schieppati M, Tredici G. Protective effect of glutathione on cisplatin neurutoxicity in rats. Int J Radiat Oncol Biol Phys 1994; 29:771–776.

    PubMed  CAS  Google Scholar 

  6. Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DGR) of rats after chronic cisplatin administrations. Histol Histopathol 1995; 10:837–845.

    PubMed  CAS  Google Scholar 

  7. Tredici G, et al. Effect of recombinant nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 1999; 159:551–558.

    Article  PubMed  CAS  Google Scholar 

  8. De Koning P, Neijt JP, Jennekens FG, Gispen WH. Evaluation of cis-diamminedichloroplatinum II (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 1987; 89:81–87.

    Article  PubMed  Google Scholar 

  9. Yalcin S, et al. Protective effect of amifostine against cisplatin induced motor neuropathy in rat. Med Oncol 2003; 20:175–180.

    Article  PubMed  CAS  Google Scholar 

  10. Yalcin S, et al. Protection against cisplatin induced nephrotoxicity by recombinant human erythropoietin. Med Oncol 2003; 20:169–174.

    Article  PubMed  CAS  Google Scholar 

  11. Cavaletti G, et al. Morphometric study of sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 1992; 84:364–371.

    Article  CAS  Google Scholar 

  12. Maxwell HP, et al. Sites of erythropoietin production. Kidney International 1997; 51:393–401.

    Article  PubMed  CAS  Google Scholar 

  13. Orhan B, Yalcin S, Evrensel T, Kurt E, Manavoglu O, Erbas T. Does cisplatin stimulate erythropoietin secretion from the peritubular cells? Clin Nephrology 1998; 50:202–203.

    CAS  Google Scholar 

  14. Yalcin S, Orhan B. Recombinant human erythropoietin in the treatment of chronic anemia of cancer (Correspondence). Acta Haematologica 1998; 100:115.

    Article  PubMed  CAS  Google Scholar 

  15. Orhan B, Yalcin S. Comments on: What are cancer patients willing to pay for prophylactic epoetin alfa—a cost benefit analysis (Correspondence). Cancer 1999; 15:1095–1096.

    Article  Google Scholar 

  16. Birgegård G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anemia for stimulation. Br J Haematol 1989; 72:462–466.

    PubMed  Google Scholar 

  17. Beguin Y, Baron F, Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after auotologous hematopoietic stem cell transplantation. Haematol 1998; 12:1076–1081.

    Google Scholar 

  18. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266:F360–366.

    PubMed  CAS  Google Scholar 

  19. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hipocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76:105–116.

    Article  PubMed  CAS  Google Scholar 

  20. Digicaylioglu M, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995; 92:3717–3720.

    Article  PubMed  CAS  Google Scholar 

  21. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem 1999; 72:2565–2571.

    Article  PubMed  CAS  Google Scholar 

  22. Cerami A, Brines ML, Ghezzi P, Crami CJ. Effects of epoetin alpha on the central nervous system. Sem Oncol 2001; 28(2)(Suppl 8):66–70.

    Article  CAS  Google Scholar 

  23. Celik M, et al. Erythropoietin prevents motor neuron apopitosis and neurologic disability in experimental spinal cord injury. Proc Natl Acad Sci USA 2002; 99:2258–2263.

    Article  PubMed  CAS  Google Scholar 

  24. Junk AK, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002; 99:10659–10664.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ali Osman Sönmez Oncology Hospital, Ankara, Turkey

    Bulent Orhan

  2. School of Medicine, Department of Neurology, Hacettepe University, Ankara, Turkey

    Gulay Nurlu

  3. School of Medicine, Department of Histology & Embryology, Hacettepe University, Ankara, Turkey

    Dilara Zeybek & Sevda Muftuoglu

  4. Institute of Oncology, Department of Medical Oncology, Sihhiye, Hacettepe University, 06100, Ankara, Turkey

    Suayib Yalcin (Assoc. Prof. of Medicine)

Authors
  1. Bulent Orhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suayib Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gulay Nurlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dilara Zeybek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sevda Muftuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suayib Yalcin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orhan, B., Yalcin, S., Nurlu, G. et al. Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats. Med Oncol 21, 197–203 (2004). https://doi.org/10.1385/MO:21:2:197

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:21:2:197

Key Words

Search

Navigation